Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Anti-Inflammatory Agents for        CNS Diseases     Brian J. Piper, Ph.D., M.S.        piperbj@husson.edu                ...
Objectives• Pharmacy students should be:  – familiar with pharmacotherapies for Multiple    Sclerosis (see also DiPiro cha...
Cells in Brain Compared                                  Neurons Glia           size                   large              ...
Blood Brain Barrier                                                                  <- Endothelial cells           Astroc...
Microglia• Frequency: 10% of all glia• States     – scanning: evaluate environment for sick cellular       elements     – ...
Multiple Sclerosis   •   neurodegenerative disorder of CNS   •   autoimmune   •   Women = 1/200; Men = 1/400   •   myelin ...
Expanded Disability Status Scale• Neurologist rates various functional systems (FS)  (visual, cerebral, cerebellar, sensor...
Multiple Sclerosis SubtypesRelapsing Remitting85%Primary Progressive15%Example patient (20 sec – 3:55): http://www.youtube...
Interferon β • What:      – IFNβ-1a: Chinese hamster ovary, glycosylation +      – IFN β-1b: E coli, glycosylation - • Ind...
Inverse Relationship Between Effect         Size of Drug & Sample SizeDrug                       Dependent Measure        ...
Disease Modifying Treatment    • Suggestive MS patients randomized to ITFβ1a      (N=154, 22 μg s.c./week) or placebo (N=1...
ITFβ1a & Neurodegeneration    • Suggestive MS patients randomized to ITFβ1a      (N=154, 22 μg s.c./week) or placebo (N=15...
Glatiramer Acetate• Structure: Glu-Lys-Ala-Tyr (also found in  myelin basic protein)• MOA: ?, decoy• Indications: ↓ relaps...
Glatiramer & Neurodegeneration     • black holes:          – lesions initially appear hypointense on T1 scans          – 4...
MS Substrates •   1) reactive T lymphocytes cross BBB •   2) trigger inflammation •   3) axon demyelination •   4) nerve d...
MOA of Natalizumab (Tysabri) • Humanized mouse antibody (-zumab) • Binds to α4 integrinsSelewski et al. (2010). American J...
Adverse Effects of Natalizumab• Anti-natalizumab antibodies (5%)• Hypersensitivity reaction (4%)• Progressive Multifocal L...
Natalizumab Evaluation • RRMS with score < 5 on EDSS randomized to   natalizumab (300 mg, i.v. 1x/month; N=627) or   place...
Alzheimer’s Disease ProjectionsSource: http://strategicallyspeaking.com/register/AD2/monograph/index.html
Neuroinflammation & AD    • COX1: ↑ in activated microglia    • COX2: high levels in pyramidal neuronsMcGreer & McGreer (2...
Do COX Inhibitors Prevent AD?• Non-demented older                                                     --------------------...
Summary• Interferon β1A/B & Glatiramer Acetate are 1st  line treatments followed by Natalizumab for  MS.• Blocking inflamm...
MRIT1 & hypointensity    T2 & hyperintensity
Upcoming SlideShare
Loading in …5
×

Anti Inflammation agents for CNS

This PPT is part of a lecture given to second year pharmacy students in a pharmacology & toxicology class.

  • Login to see the comments

Anti Inflammation agents for CNS

  1. 1. Anti-Inflammatory Agents for CNS Diseases Brian J. Piper, Ph.D., M.S. piperbj@husson.edu February 13, 2013
  2. 2. Objectives• Pharmacy students should be: – familiar with pharmacotherapies for Multiple Sclerosis (see also DiPiro chapter 64) – able to evaluate the role of anti-inflammatory agents in other neurodegenerative diseases (AD).
  3. 3. Cells in Brain Compared Neurons Glia size large small action potential yes no # few manySantiago division inRamon y adulthood no* yesCajal types pyramidal (cortex) oligodendrocytes (CNS) Purkinje (cerebellum) Schwann cells (PNS) *except hippocampus & olfactory nerve
  4. 4. Blood Brain Barrier <- Endothelial cells Astrocyte -> <- Microglia <- NeuronBentivoglio et al. (2011). Brain Research Reviews, 66, 152-173.
  5. 5. Microglia• Frequency: 10% of all glia• States – scanning: evaluate environment for sick cellular elements – activated: • divide • move • phagocytose • Release pro-inflammatory cytokines (IL-1α, IL-1β, TNF- α)Brodal, P. (2010). The central nervous system. Chapter 2.Humorous Overview: http://www.scq.ubc.ca/creeping-into-your-head-a-brief-introduction-to-microglia/
  6. 6. Multiple Sclerosis • neurodegenerative disorder of CNS • autoimmune • Women = 1/200; Men = 1/400 • myelin > neuronsJean Martin Charcot“father of neurology” 1825 - 1893
  7. 7. Expanded Disability Status Scale• Neurologist rates various functional systems (FS) (visual, cerebral, cerebellar, sensory, pyramidal)• Total – 0: normal neurological exam – 1: minimal disability on 1 FS – 2.5: minimal disability on 2 FS – 4.5: able to walk without aid for 300 m – 6.5: constant bilateral support – 8.5: bedridden but some self-care maintained – 9.5: unable to communicate/eat/swallow – 10: death due to MSKurtzke, J. F. (1983). Neurology, 33(11), 1444-1452.
  8. 8. Multiple Sclerosis SubtypesRelapsing Remitting85%Primary Progressive15%Example patient (20 sec – 3:55): http://www.youtube.com/watch?v=-BGBSsKBrbI
  9. 9. Interferon β • What: – IFNβ-1a: Chinese hamster ovary, glycosylation + – IFN β-1b: E coli, glycosylation - • Indication: to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations in RRMS • MOA: ? – ↓ BBB permeability – Binds to IFN transmembrane receptors, reduces activation of myelin reactive T cells – ↑ Nerve Growth Factor release from astrocytes • AE: flu-like symptoms, depressionMendes & Sa (2011). Arq Neuropsiquiatry, 69(3), 536-543.
  10. 10. Inverse Relationship Between Effect Size of Drug & Sample SizeDrug Dependent Measure Sample Size/groupL-DOPA motor function 5-10heroin pain 5-10sertraline delayed ejaculation 10methylphenidate cognitive vigilance 15sertraline antidepressant 100(s)tacrine cognitive enhancement 100(s)riluzole survival (ALS) 1,000 Effect Size = MeanDrug – MeanPlacebo How to ↑Effect Size 1) numerator --------------------------------------------- Individual Differences 2) denominator 3) sensitive measures
  11. 11. Disease Modifying Treatment • Suggestive MS patients randomized to ITFβ1a (N=154, 22 μg s.c./week) or placebo (N=155) for 2 years 569 ----------------------------------------------------------------------------------------- 252 CDMS: Clinically Definite Multiple Sclerosis = 2nd relapseComi et al. (2001). Lancet, 357, 1576-1582.
  12. 12. ITFβ1a & Neurodegeneration • Suggestive MS patients randomized to ITFβ1a (N=154, 22 μg s.c./week) or placebo (N=155) for 2 years T2 = reversed (white matter-dark)Comi et al. (2001). Lancet, 357, 1576-1582.
  13. 13. Glatiramer Acetate• Structure: Glu-Lys-Ala-Tyr (also found in myelin basic protein)• MOA: ?, decoy• Indications: ↓ relapse frequency in RRMS• AE: injection site reactions (50%)
  14. 14. Glatiramer & Neurodegeneration • black holes: – lesions initially appear hypointense on T1 scans – 40% of lesions progress to darkness intermediate between gray matter & CSF • RRMS randomized to glatiramer (20 mg/day) or placebo for 8 months placebo glatiramer (N = 120) (N = 119) 1 month 33.9% 31.3% 8 months 31.4% 15.6%* *p < .05Fillipi et al. (2001). Neurology, 57, 731-733.
  15. 15. MS Substrates • 1) reactive T lymphocytes cross BBB • 2) trigger inflammation • 3) axon demyelination • 4) nerve damage Adhesion ExtravasationVCAM: Vascular Cell Adhesion Molecule; MadCAM: Muccosal adressin Cell Adhesion Molecule
  16. 16. MOA of Natalizumab (Tysabri) • Humanized mouse antibody (-zumab) • Binds to α4 integrinsSelewski et al. (2010). American Journal of Neuroradiology, 31, 1588-1590.
  17. 17. Adverse Effects of Natalizumab• Anti-natalizumab antibodies (5%)• Hypersensitivity reaction (4%)• Progressive Multifocal Leukoencephalopathy (0.1%) – JC (John Cunningham) Virus – loss of oligodendrocytes – fatalHorga & Tintore (2011). Neurologia, 26(6), 357-368.
  18. 18. Natalizumab Evaluation • RRMS with score < 5 on EDSS randomized to natalizumab (300 mg, i.v. 1x/month; N=627) or placebo (N=315) for two years 29% # of new T2 Hyperintense Lesions Placebo Natalizumab 17% 1 Year 6.1 1.2 2 Year 11.0 1.9* * P < .0001Polman et al. (2006). New England Journal of Medicine, 354(9), 899-910.
  19. 19. Alzheimer’s Disease ProjectionsSource: http://strategicallyspeaking.com/register/AD2/monograph/index.html
  20. 20. Neuroinflammation & AD • COX1: ↑ in activated microglia • COX2: high levels in pyramidal neuronsMcGreer & McGreer (2007). Neurobiology of Aging, 28, 639-647.
  21. 21. Do COX Inhibitors Prevent AD?• Non-demented older ----------------------------------------------------- (55+) adults (N=6,989) were followed for 7 years• Prescriptions of NSAIDs were examinedVeld et al. (2001). New England Journal of Medicine, 346(21), 1515-1521.
  22. 22. Summary• Interferon β1A/B & Glatiramer Acetate are 1st line treatments followed by Natalizumab for MS.• Blocking inflammation has been useful to prevent, but not treat, Alzheimer’s Disease.
  23. 23. MRIT1 & hypointensity T2 & hyperintensity

×